{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Ribavirin&page=2", "query": { "intervention": "Placebo Ribavirin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 84, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Ribavirin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Ribavirin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T15:50:58.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01257204", "title": "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 196, "start_date": "2010-12", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257204" }, { "nct_id": "NCT01435044", "title": "Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "GS-0938", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Placebo to match sofosbuvir", "type": "DRUG" }, { "name": "Placebo to match GS-0938", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2011-09", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 42, "location_summary": "Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01435044" }, { "nct_id": "NCT01859962", "title": "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "PPI-668", "type": "DRUG" }, { "name": "BI 207127 Dose 1", "type": "DRUG" }, { "name": "BI 207127 Dose 2", "type": "DRUG" }, { "name": "Faldaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "BI 207127 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Presidio Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2013-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859962" }, { "nct_id": "NCT01193361", "title": "Ph IIA Study (SOC +/- NS5B)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-791325", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peg-interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2010-10", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 10, "location_summary": "Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193361" }, { "nct_id": "NCT01273064", "title": "Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "CTS-1027", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conatus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2011-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-06-11", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273064" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" }, { "nct_id": "NCT01278134", "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus placebo", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 18, "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278134" }, { "nct_id": "NCT00274495", "title": "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C Infection", "Fatty Liver" ], "interventions": [ { "name": "Rosiglitazone and Pegasys/Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2006-01", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274495" }, { "nct_id": "NCT00851890", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus Infection" ], "interventions": [ { "name": "ABT-333", "type": "DRUG" }, { "name": "Placebo for ABT-333", "type": "OTHER" }, { "name": "Pegylated interferon", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2009-03", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 7, "location_summary": "Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00851890" }, { "nct_id": "NCT00983853", "title": "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "telaprevir or matching placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin (fixed dose)", "type": "DRUG" }, { "name": "ribavirin (weight-based dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 62, "start_date": "2009-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-10-10", "last_synced_at": "2026-09-30T15:50:58.008Z", "location_count": 11, "location_summary": "Beverly Hills, California • San Diego, California • San Francisco, California + 8 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00983853" } ] }